spacer
home > epc > winter 2009 > patent problems
PUBLICATIONS
European Pharmaceutical Contractor

Patent Problems

If there was ever a question about the importance of intellectual property (IP) and patent protection to the pharmaceutical industry, it is about to be answered. The world’s top drug makers are shuffling towards the edge of a patent cliff that may cost the industry £70 billion in annual sales by 2016, as key product patents expire and cheap generic versions of their blockbuster medicines hit the market.

The industry will no doubt survive the fall, but patents are likely to become even more important to corporations, as they reformulate their strategies and become more competitive and acquisitive. Those companies that spend the time and money up front on patent strategy and awareness are likely to emerge the strongest.

HIGH PROFILE EXPIRIES

Even before the global economic recession hit, the pharmaceutical industry was beginning to steady itself for an uncertain future. Perhaps the most conspicuous of these high profile expiries will be the core patents protecting the bestselling drug of all time: Pfizer’s cholesterol-lowering medicine, LipitorTM. In November 2011, these patents will expire, and industry experts predict that, within the first year, generic competition will cost Pfizer approximately 80 per cent of the £8 billion it receives annually from global sales of the drug. This would put the current combined value of the two or three core patent families protecting it at approximately £6.5 billion a year – the equivalent to approximately 20 per cent of Pfizer’s total sales for 2008.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Haydn Evans, VP of EU Search Operations at CPA Global, looks after operations for the company’s European search and landscaping teams. He has worked in the IP industry for more than 10 years and, prior to joining CPA Global, was employed as a Senior Analyst & Strategy Manager for GE Healthcare (formerly as part of Amersham Plc).

spacer
Haydn Evans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement